These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 19468980)
1. Haematologists specializing in the treatment of MPDs coordinated a combined effort with experts in other fields, in this case cardiology, dermatology and psychiatry. Introduction. Rønnov-Jessen D Hematol Oncol; 2009 Jun; 27 Suppl 1():1. PubMed ID: 19468980 [No Abstract] [Full Text] [Related]
2. [Recommendations for the cytogenetic management of myeloproliferative syndromes proposed by the French Group for Cytogenetic Hematology]. Groupe Français de Cytogénétique Hématologique (GFCH) Pathol Biol (Paris); 2004 Jun; 52(5):241-4. PubMed ID: 15217703 [No Abstract] [Full Text] [Related]
3. The Checklist Manifesto in action: integrating depression treatment into routine cardiac care. Schuster JM; Belnap BH; Roth LH; Rollman BL Gen Hosp Psychiatry; 2016; 40():1-3. PubMed ID: 26916974 [No Abstract] [Full Text] [Related]
4. Myeloproliferative disorder therapy: assessment and management of adverse events--a psychiatrist's perspective. McDonald G Hematol Oncol; 2009 Jun; 27 Suppl 1():14-6. PubMed ID: 19468981 [TBL] [Abstract][Full Text] [Related]
6. [Rational diagnosis and therapy in hematology. A short summary]. Gross R Med Welt; 1982 Feb; 33(5):155-62. PubMed ID: 7070270 [No Abstract] [Full Text] [Related]
7. The psychological needs of adolescents and young adults with a diagnosis of myeloproliferative neoplasms: a systematic scoping review of the literature. Houlihan T; Fortune DG; Keohane C; Richards HL Leuk Lymphoma; 2024 May; 65(5):679-683. PubMed ID: 38324010 [No Abstract] [Full Text] [Related]
8. [Psychiatry--prevention and specializing. Danish Society of Psychiatry]. Bredkjaer SR; Jørgensen P Ugeskr Laeger; 2005 Mar; 167(12-13):1402. PubMed ID: 15832722 [No Abstract] [Full Text] [Related]
10. [From competition to consultation]. Boehncke WH; Gilliet M Rev Med Suisse; 2013 Apr; 9(380):699-700. PubMed ID: 23621037 [No Abstract] [Full Text] [Related]
11. Myeloproliferative disorders: a time of new definitions. Outflow from New Horizons in Haematology Meeting, 9-10 March 2007. Skoda R; Barbui T; Reilly JT Eur J Haematol Suppl; 2007 Oct; (68):1. PubMed ID: 17727555 [No Abstract] [Full Text] [Related]
12. Myeloproliferative disorder therapy: assessment and management of adverse events--a cardiologist's perspective. Kenny D Hematol Oncol; 2009 Jun; 27 Suppl 1():8-10. PubMed ID: 19468985 [TBL] [Abstract][Full Text] [Related]
13. Defining targets in myeloproliferative disorders: reflecting on what is important. Griesshammer M Hematol Oncol; 2009 Jun; 27 Suppl 1():2-4. PubMed ID: 19468984 [TBL] [Abstract][Full Text] [Related]
14. Myeloproliferative disorder therapy: assessment and management of adverse events--a dermatologist's perspective. Soutou B; Aractingi S Hematol Oncol; 2009 Jun; 27 Suppl 1():11-3. PubMed ID: 19468982 [TBL] [Abstract][Full Text] [Related]
19. Perinatal psychiatry: the challenges of making rational treatment decisions at the interface of psychiatry and obstetrics. Freeman MP J Clin Psychiatry; 2009 Sep; 70(9):1311-2. PubMed ID: 19818246 [No Abstract] [Full Text] [Related]